finansavisen.no/helse/2024/01/… Finansavisen

Updated Timeline for Reporting on Randomized UV1 Phase II Trial INITIUM in Malignant #Melanoma: Topline Results expected in March 2024 ⏳ newsweb.oslobors.no/message/608558

Resultater fra Ultimovacs-studie er snart klare: Topplinjedataene fra føflekkreftstudien til Ultimovacs kommer i mars. medwatch.no/nyheter/legemi…

Read the interview with Espen Basmo Ellingsen in Drug Target Review - Immuno-oncology innovations redefining cancer treatment in 2024 #CancerResearch #immunotherapy #biotech drugtargetreview.com/article/125151…

Ultimovacs Receives FDA #FastTrack Designation for UV1 Cancer Vaccine for the Treatment of Patients with Unresectable #Mesothelioma #biotech #immunotherapy #Phase2 newsweb.oslobors.no/message/609798

Thanks for the shout-out OncLive.com 💫 onclive.com/view/fda-grant…

FDA Fast Tracks Ultimovacs' Novel Cancer Vaccine for Malignant Pleural Mesothelioma pharmexec.com/view/fda-fast-… via Pharmaceutical Executive

Read about the randomized Ph2 FOCUS trial in head and neck cancer, expected readout H2 2024: frontiersin.org/journals/oncol… #cancerresearch #immunotherapy #cancervaccine

Our CEO Carlos de Sousa was at Finansavisen TV today - watch the interview here: tv.finansavisen.no/m/Zb1tE1XC/ult…? #immunotherapy #CancerResearch

Excited to start the week with more good news: Orphan Drug Designation for UV1 Cancer Vaccine for the Treatment of #Mesothelioma from EU Medicines Agency #immunotherapy newsweb.oslobors.no/message/611188

medwatch.no/nyheter/legemi… from MedWatch News

finansavisen.no/teknologi/2024…

UV1 Receives Orphan Drug Designation From EMA in Mesothelioma onclive.com/view/uv1-recei… via @onclive

A positive opinion from EU Medicines Agency for Ultimovacs #uv1 #mesothelioma vaccine combination #therapy, shortly after ftd from U.S. FDA #vaccinenation #vaccines #vaccine #cancer #cancerresearch #therapeutic #ultimovacs vaccinenation.org/therapeutic/ul…

biopharmaboardroom.com/news/26/1608/u… #cancerresearch #biotech

biostock.se/en/2024/02/ult… #CancerResearch #orphandrugdesignation #biotech #mesothelioma

Ultimovacs is a #biotech company developing novel immunotherapies against cancer. Watch executive interview with Jens Bjørheim, CMO of Ultimovacs, who discusses the company’s key asset, UV1, and upcoming milestones/catalyst: ow.ly/XOcm50QIatF Ultimovacs $ULTI #OSE

Congrats to the NIPU investigator team with publication in European Journal of Cancer! #mesothelioma #phase2

Ultimovacs — Peer-reviewed publication reiterates UV1’s potential. $ULTI #OSE Ultimovacs ow.ly/BPY650QKJEg